Imugene Limited (ASX: IMU), a prominent player in the immuno-oncology field, has released an encouraging update on its Phase 1 MAST trial, which evaluates the safety and efficacy of the novel oncolytic virus, CF33-hNIS (VAXINIA), used both as monotherapy and in combination with pembrolizumab (KEYTRUDA). As the trial progresses, noteworthy outcomes are emerging, particularly in […]
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. This potent combination significantly improved overall survival (OS) and progression-free survival (PFS) for patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Highlighted Findings from the EV-302 Study […]
Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck’s KEYTRUDA for first-line treatment of metastatic non-small cell lung cancer (NSCLC). The data was presented at the IASLC 2023 World Conference on Lung Cancer and focuses on patients without actionable genomic alterations. EVOKE-02 Preliminary Analysis: Notable Response Rates Across […]
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. The trial aims to investigate the safety and efficacy of ENB-003, the company’s lead product, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). This Phase 1/2a study is an open-label, […]
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation by the US Food and Drug Administration (FDA). The breakthrough therapy designation for the combination is for its use as adjuvant treatment of high-risk melanoma in patients […]
Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination with Merck’s Keytruda and platinum chemotherapy has been now approved by the US Food and Drug Administration (FDA) for the initial treatment of patients with metastatic, non-squamous, non-small cell lung […]
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of head and neck squamous cell carcinoma (HNSCC) both as a monotherapy and in combination with Merck’s pembrolizumab (KEYTRUDA). The fast track designation for the interleukin 2 (IL-2)-based biologic is in […]
PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for the treatment of HPV16-positive head and neck cancer that is recurrent or metastatic. The US-based clinical-stage immunotherapy company is currently evaluating the combination of PDS0101 and KEYTRUDA in the VERSATILE-002 […]
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]